Advanced Bionics Grab Gives Boston Scientific Neurostim Growth Platforms
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is prepared to pay up to $4 bil. for neuromodulation systems developer Advanced Bionics as a means to add high-growth potential beyond its core vascular intervention business
You may also be interested in...
Mergers & Acquisitions In Brief
Ecolab's Microtek deal focuses on infection prevention: Acquisition of Microtek Medical for $274 million is intended to expand Ecolab's infection prevention offerings, Ecolab announces Aug. 7. Microtek's surgical drapes, disposable linens, and fluid and medical waste management equipment will dovetail with Ecolab's surface disinfectants, instrument cleaning detergents and surgical hand scrubs. Microtek reported second quarter revenue of $38.5 million, up 6.8%. Ecolab, with Q2 sales of $1.4 billion (up 11%) bills itself as "the world's leading provider of cleaning, food safety and health protection products and services". Ecolab will pay $6.30 in cash for each of Microtek's 43.5 million shares outstanding - representing a 34% premium over Microtek stock's Aug. 7 closing price of $4.69...
Mergers & Acquisitions In Brief
Ecolab's Microtek deal focuses on infection prevention: Acquisition of Microtek Medical for $274 million is intended to expand Ecolab's infection prevention offerings, Ecolab announces Aug. 7. Microtek's surgical drapes, disposable linens, and fluid and medical waste management equipment will dovetail with Ecolab's surface disinfectants, instrument cleaning detergents and surgical hand scrubs. Microtek reported second quarter revenue of $38.5 million, up 6.8%. Ecolab, with Q2 sales of $1.4 billion (up 11%) bills itself as "the world's leading provider of cleaning, food safety and health protection products and services". Ecolab will pay $6.30 in cash for each of Microtek's 43.5 million shares outstanding - representing a 34% premium over Microtek stock's Aug. 7 closing price of $4.69...
Boston Scientific Inks Pact With Aspect For Depression, Alzheimer’s Tests
Boston Scientific will enhance its neurostimulation business and reap profits from future Aspect Medical SystemsBIS brain-monitoring technology for depression under a $25 mil. development deal announced May 23